News and Announcements
Cellmid Collaborates on Early Diagnosis of Colorectal Cancer
- Published July 29, 2013 9:57AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
- Cellmid signed collaboration agreement with Abcodia for testing midkine in longitudinal serum samples
- Abcodia has exclusive access to a unique collection of 5,000,000 serum samples
- Initially targeting validation of midkine as early marker of colorectal cancer
Sydney, Monday 29 July 2013: Cellmid Limited (ASX:CDY) signed a collaboration agreement with Abcodia Ltd, the UK biomaker validation company, for the testing of midkine (MK) in their collection of longitudinal serum samples using Cellmid’s MK-ELISA.
The initial objective of the collaboration to validate midkine as a useful marker for the screening and early diagnosis of colorectal cancer. Serum samples will be provided by Abcodia and testing will be carried out by Cellmid.
To read the full ASX announcement, please download the document below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
